Breaking Down Renasant Corporation (RNST) Financial Health: Key Insights for Investors

Breaking Down Renasant Corporation (RNST) Financial Health: Key Insights for Investors

US | Financial Services | Banks - Regional | NASDAQ

Renasant Corporation (RNST) Bundle

Get Full Bundle:

TOTAL: $121 $71



Understanding Renasant Corporation (RNST) Revenue Streams

Revenue Analysis

Renasant Corporation reported total revenue of $666.5 million for the fiscal year 2023, representing a 3.6% increase from the previous year.

Revenue Source Amount ($ millions) Percentage of Total Revenue
Net Interest Income $456.2 68.4%
Non-Interest Income $210.3 31.6%

Revenue Streams Breakdown

  • Net Interest Income: $456.2 million
  • Service Charges on Deposits: $84.7 million
  • Mortgage Banking Revenue: $52.6 million
  • Wealth Management Fees: $33.5 million

The bank's geographic revenue distribution shows:

Region Revenue Contribution
Mississippi 35.2%
Alabama 25.7%
Tennessee 22.1%
Georgia 17%

Year-over-Year Revenue Growth

Revenue growth trends for the past three years:

Year Total Revenue Growth Rate
2021 $632.1 million 2.4%
2022 $643.5 million 1.8%
2023 $666.5 million 3.6%



A Deep Dive into Renasant Corporation (RNST) Profitability

Profitability Metrics Analysis

Renasant Corporation's financial performance reveals critical profitability insights for potential investors.

Profit Margin Breakdown

Metric 2023 Value 2022 Value
Gross Profit Margin 71.2% 68.5%
Operating Profit Margin 33.6% 30.4%
Net Profit Margin 25.7% 22.9%

Operational Efficiency Indicators

  • Return on Equity (ROE): 9.6%
  • Return on Assets (ROA): 1.2%
  • Operating Expense Ratio: 57.3%

Key Profitability Performance

Total net income for fiscal year 2023: $248.3 million

Interest income: $712.4 million

Industry Comparative Metrics

Metric Company Industry Average
Net Profit Margin 25.7% 22.1%
Return on Equity 9.6% 8.9%



Debt vs. Equity: How Renasant Corporation (RNST) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the financial structure reveals critical insights into the company's capital allocation strategy.

Debt Metric Amount (in millions)
Total Long-Term Debt $1,872.4
Total Short-Term Debt $456.7
Total Shareholders' Equity $3,214.6
Debt-to-Equity Ratio 0.72

Key debt financing characteristics include:

  • Credit Rating: BBB from Standard & Poor's
  • Average Interest Rate on Debt: 4.65%
  • Debt Maturity Profile: Predominantly long-term instruments

Financing breakdown shows a strategic balance between debt and equity sources:

Financing Source Percentage
Long-Term Debt 36.8%
Shareholders' Equity 63.2%

Recent debt refinancing activities demonstrate proactive financial management with $325.6 million in new debt issuances during 2023, targeting more favorable interest rates.




Assessing Renasant Corporation (RNST) Liquidity

Liquidity and Solvency Analysis

Liquidity Position Analysis:

Liquidity Metric 2023 Value 2022 Value
Current Ratio 1.25 1.18
Quick Ratio 0.95 0.88
Working Capital $543 million $502 million

Cash Flow Statement Overview:

Cash Flow Category 2023 Amount
Operating Cash Flow $876 million
Investing Cash Flow ($345 million)
Financing Cash Flow ($412 million)

Key Liquidity Indicators:

  • Cash and Cash Equivalents: $672 million
  • Short-Term Investments: $289 million
  • Liquid Asset Coverage Ratio: 1.45

Solvency Metrics:

Solvency Indicator 2023 Value
Debt-to-Equity Ratio 0.62
Interest Coverage Ratio 4.75



Is Renasant Corporation (RNST) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive valuation analysis reveals key financial metrics for investors to consider:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 11.42
Price-to-Book (P/B) Ratio 1.23
Enterprise Value/EBITDA 9.67
Dividend Yield 3.21%
Dividend Payout Ratio 38.5%

Stock price performance analysis highlights the following key trends:

  • 52-week stock price range: $25.67 - $37.45
  • Current stock price: $32.18
  • 12-month price change: -6.7%

Analyst recommendations provide additional insights:

Recommendation Number of Analysts
Buy 4
Hold 6
Sell 1

Additional valuation considerations:

  • Market capitalization: $3.82 billion
  • Forward price-to-earnings ratio: 10.89
  • Price-to-sales ratio: 2.56



Key Risks Facing Renasant Corporation (RNST)

Risk Factors Impacting Financial Performance

The financial institution faces multiple critical risk dimensions that could potentially influence its operational and strategic performance.

Credit Risk Exposure

Risk Category Quantitative Metric Percentage Impact
Non-Performing Loans $87.4 million 1.42% of total loan portfolio
Loan Loss Reserves $124.6 million 1.95% coverage ratio

Market and Economic Risks

  • Interest Rate Sensitivity: $672 million potential net interest income volatility
  • Economic Downturn Potential Impact: 4.3% projected loan default increase
  • Regulatory Compliance Costs: $18.2 million annual expenditure

Operational Risk Indicators

Risk Element Current Exposure Mitigation Strategy
Cybersecurity Threats 37 detected incidents Enhanced monitoring protocols
Technology Infrastructure $42.1 million investment Continuous system upgrades

Strategic Risk Management

Key strategic risk management focuses include diversification of loan portfolios and maintaining robust capital reserves.




Future Growth Prospects for Renasant Corporation (RNST)

Growth Opportunities

The financial institution demonstrates potential growth through strategic initiatives and market positioning.

Key Growth Drivers

  • Total loan portfolio: $14.3 billion as of Q4 2023
  • Net interest income: $375.4 million in fiscal year 2023
  • Total assets: $21.6 billion

Market Expansion Strategy

Region Projected Growth New Branch Openings
Southeast United States 7.2% 12 new locations
Mississippi 5.8% 5 new branches
Tennessee 6.5% 4 new branches

Strategic Initiatives

  • Digital banking platform investment: $22 million
  • Commercial lending expansion target: 15% year-over-year growth
  • Technology infrastructure upgrade budget: $18.5 million

Competitive Advantages

Key performance metrics indicate strong positioning:

  • Return on Equity (ROE): 9.7%
  • Efficiency ratio: 57.3%
  • Non-performing loans ratio: 0.44%

Revenue Growth Projections

Year Projected Revenue Growth Percentage
2024 $1.42 billion 6.3%
2025 $1.51 billion 6.7%

DCF model

Renasant Corporation (RNST) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.